Effimune, J&J deal

Johnson & Johnson’s Janssen Biotech Inc. unit exercised an option to acquire exclusive, worldwide development and commercialization rights to FR104 from OSE Immunotherapeutics S.A. (Euronext:OSE, Nantes, France). Janssen gained the option under a 2013 deal with Effimune S.A.S., which merged with Orphan Synergy Europe Pharma S.A. in May to form OSE. Janssen exercised its option following the completion of a Phase I trial of the pegylated monovalent antibody fragment antagonist of CD28 receptor in healthy volunteers. ...